Considering the most advanced stage of NSCLC and the targeted therapies available, Figure 4 describes in detail the therapeutic pipeline recommended for each genetic alteration and according to the level of PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.